This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

When the Fed Responds, These Stocks Will Correct

After the Fed makes its big announcement, NLY and HTS should spike higher, and then the "sell on the news" reaction may quickly follow.

If you have a big position in either you might want to take half off the table on the day the good news of MQE breaks with the hope of buying back at least 10% lower.

Drug Stocks and Health Care

If you invested months ago in Big Pharmaceutical companies including Pfizer (PFE - Get Report) you've had a rich and rewarding ride. Look at the chart below that compares Pfizer's multi-year price to its dividend yield. PFE Dividend Yield Chart PFE Dividend Yield data by YCharts

Pfizer has had a brilliant strategy of beefing up its product pipeline while unloading whole divisions in spin-offs and public offerings.

Under CEO Ian Read, who as of Feb. 24 owns almost 879,000 shares worth nearly $20,500,000 at the Wednesday share price of $23.33, PFE has been doing some "unwinding."

The company has systematically sold off some big assets it acquired through mega-mergers, including the 2009 purchase of Wyeth Pharmaceuticals for $68 billion.

In April Pfizer agreed to sell its nutrition unit for $11.85 million to Nestle SA NESTLE (NSRGY), a company I believe is undervalued and attractively priced.

Then, in the first week of June, Pfizer announced that it's preparing to sell a minority state in its animal-health unit as part of the drug maker's plan to sell assets and sharpen its focus on human drugs.

It named the animal-health business Zoetis. PFE plans to make Zoetis a standalone company by July 2013, but first it's working on an initial public offering. So far the IPO date has not been announced.

Pfizer's animal-health unit may be valued at between $15 billion and $18 billion when it separates from PFE, according to a recent Nasdaq report .

"Pfizer Animal Health is a dynamic business with strong fundamentals, an expanding and loyal direct customer base and a proven management team," said Pfizer CEO Read. Read also repeated Pfizer's commitment to launch share buybacks with the proceeds of a prospective sale.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
HTS $18.55 0.00%
NLY $10.25 0.00%
PFE $35.27 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs